Conference Coverage
Conference Coverage
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
Latest News
Residency match process under scrutiny again, this time by AMA
AMA may study alternatives to the current residency matching program in an effort to improve residents’ compensation and other job-related issues...
Latest News
Imaging techniques will revolutionize cancer detection, expert predicts
Jennifer Barton, PhD, and her colleagues are developing an OCT/fluorescence imaging falloposcope that is 0.8 mm in diameter, flexible, and...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Latest News
T-DXd active in many solid tumors; ‘shift in thinking’
T-DXd is a potential new treatment option for patients with HER2-expressing solid tumors, experts say.
Conference Coverage
CAR T-cell benefit in lenalidomide-refractory myeloma
“Early CAR Ts demonstrating efficacy and safety and prior lines of treatment impact survival from CAR T in myeloma. Can this also be true for...
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Conference Coverage
Reducing risk for thrombosis in patients with lung cancer
This risk may be increased by certain cancer drugs, which seems to be the case for the combination of innovative targeted therapies lazertinib-...
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...